Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete | Latest News RSS feed

Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete - Latest News


Farxiga gets positive result in DECLARE-TIMI 58

... trial in 17,000 patients with type-2 diabetes Farxiga met the primary composite endpoint of a statistically-significant reduction in hospitalisation for heart failure or CV death in a broad patien... read more

Doctors debate danger of popular diabetes drug after FDA amputation warning

The Scripps Health system’s hospital ... with type 2 diabetes,” she said. The drug “significantly reduced the combined risk of cardiovascular death, nonfatal myocardial infarction (heart attack) and n... read more

AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q3 2018 Results - Earnings Call Transcript

Over the past few years, we have reduced ... in hospitalization, heart failure or cardiovascular death, which is a primary endpoint that was met, but also the opportunity to go into a much broader pat... read more

Looking for another news?


2017 Brands of the Year: 5 Impact Areas

Patient ... in adults with type 2 diabetes (T2D); in its supplemental new drug applications, BI/Lilly sought a new indication that Jardiance also decreased the incidence of CV death and the risk of de... read more


Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript

In CVRM, Farxiga was accepted for review in the EU in Type ... of all-cause death, lower risk of hospitalization for heart failure, lower risk of myocardial infarction and lower risk of stroke. As a r... read more

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

1 Translational Research Institute for Metabolism and Diabetes, Florida Hospital ... and considering patient convenience and personal choices, it appears that SGLT2 inhibitors would be a reasonable al... read more

AstraZeneca: Q1 2017 Results

Continued good progress on cost control, reflecting the evolving shape of the business: - Reported R&D costs declined by 2% (up by 2% at CER) to $1,453m; Core R&D costs declined by 6% (3% at CER) to $... read more

Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials

We performed a systematic review of RCTs that compared telemedicine with usual care for the management of diabetes (type 1 and type 2 ... “smart” device (3%), customized patient-specific Web page (2%) ... read more

AstraZeneca: Q1 2017 Results

Continued good progress on cost control, reflecting the evolving shape of the business: - Reported R&D costs declined by 2% (up by 2% at CER) to $1,453m; Core R&D costs declined by 6% (3% at CER) to $... read more

AstraZeneca Full-Year and Q4 2015 Results

bringing the dividend for the full year to $2.80; the Board reaffirms its commitment to the progressive dividend policy · FY 2016 CER guidance - a low to mid single-digit percentage decline in Total R... read more

AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call Transcript

We are pleased to now offer U.S. patients a convenient device to treat type 2 ... Farxiga. The analysis demonstrated that the treatment with an SGLT2 inhibitor was associated with a lower risk of all- ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us